» Articles » PMID: 35056345

De Novo Minimal Change Disease Following Vaccination with the Pfizer/BioNTech SARS-CoV-2 Vaccine in a Living Kidney Donor

Overview
Publisher MDPI
Specialty General Medicine
Date 2022 Jan 21
PMID 35056345
Authors
Affiliations
Soon will be listed here.
Abstract

Coronavirus disease 2019 has developed as a pandemic. Immunization with the introduction of vaccines against COVID-19 seems be the only way to end this pandemic. We report on a case of a kidney donor, who developed minimal change disease (MCD) within 4 days post-vaccination with the SARS-CoV-2 BNT162b2 mRNA vaccine (Pfizer/BioNTech). She donated her kidney to her husband 4 years ago. After receiving the 1st vaccine dose, she presented with nephrotic syndrome, with complete remission 5 days later. She proceeded with the second dose of the BNT162b2 vaccine at the appointed time. Two days later, she presented with a relapse of full-blown nephrotic syndrome with preserved renal function. We performed an ultrasound-guided percutaneous kidney biopsy and the final diagnosis was consistent with minimal change disease. Oral prednisolone was promptly initiated at a dosage of 1 mg/kg daily and complete remission was achieved 10 days later. More data about this rare appearance of de novo glomerular diseases after SARS-CoV-2 vaccination are emerging and should be interpreted rigorously.

Citing Articles

Two adolescents with frequently relapsing nephrotic syndrome newly diagnosed after SARS-CoV-2 vaccination: case report and literature review.

Nakazawa E, Uchimura T, Ohyama R, Togashi H, Inaba A, Shiga K CEN Case Rep. 2025; .

PMID: 39960599 DOI: 10.1007/s13730-025-00967-6.


Minimal change disease following COVID-19 vaccination: A systematic review.

Kechagias K, Laleye J, Drmota J, Geropoulos G, Kyrtsonis G, Zafeiri M PLoS One. 2024; 19(3):e0297568.

PMID: 38442131 PMC: 10914286. DOI: 10.1371/journal.pone.0297568.


New-onset minimal change disease following the Moderna COVID-19 vaccine.

Kobayashi N, Fujisawa H, Kumagai J, Tanabe M BMJ Case Rep. 2023; 16(9).

PMID: 37714559 PMC: 10510908. DOI: 10.1136/bcr-2023-255144.


Nephrotic syndrome following COVID-19 vaccination: a systematic review.

Parikh C, Upadhyay H, Patel S, Sundararajan R, Shah D, Anand A J Nephrol. 2023; 36(9):2431-2440.

PMID: 37505405 DOI: 10.1007/s40620-023-01710-z.


Relapse of minimal change disease following the third mRNA COVID-19 vaccination: a case report and literature review.

Teragaki M, Tanaka M, Yamamoto H, Watanabe T, Takeoka J, Fukumi A CEN Case Rep. 2023; 13(1):53-58.

PMID: 37244881 PMC: 10224756. DOI: 10.1007/s13730-023-00798-3.


References
1.
Anupama Y, Patel R, Vankalakunti M . Nephrotic Syndrome Following ChAdOx1 nCoV-19 Vaccine Against SARScoV-2. Kidney Int Rep. 2021; 6(8):2248. PMC: 8257404. DOI: 10.1016/j.ekir.2021.06.024. View

2.
DAgati V, Kudose S, Bomback A, Adamidis A, Tartini A . Minimal change disease and acute kidney injury following the Pfizer-BioNTech COVID-19 vaccine. Kidney Int. 2021; 100(2):461-463. PMC: 8123374. DOI: 10.1016/j.kint.2021.04.035. View

3.
Nasr S, Kopp J . COVID-19-Associated Collapsing Glomerulopathy: An Emerging Entity. Kidney Int Rep. 2020; 5(6):759-761. PMC: 7196556. DOI: 10.1016/j.ekir.2020.04.030. View

4.
Bomback A, Kudose S, DAgati V . De Novo and Relapsing Glomerular Diseases After COVID-19 Vaccination: What Do We Know So Far?. Am J Kidney Dis. 2021; 78(4):477-480. PMC: 8230841. DOI: 10.1053/j.ajkd.2021.06.004. View

5.
Lin S, Zhu F, Meng J, Sun X, Cui J, Liang S . Clinical features of acute kidney injury in patients with nephrotic syndrome and minimal change disease: a retrospective, cross-sectional study. Chin Med J (Engl). 2021; 134(2):206-211. PMC: 7817344. DOI: 10.1097/CM9.0000000000001218. View